Neurologists and other physicians, nurse practitioners, PAs, registered nurses, and pharmacists who collaborate to provide care for patients with MS
The pathology of multiple sclerosis (MS) is complex, with alternating periods of neurologic dysfunction and periods of relative clinical stability free of new neurologic symptoms. Furthermore, there is no single clear treatment pathway. While the therapeutic landscape in MS has expanded in recent years to include an array of disease-modifying therapies, MS management requires balancing the benefits of medications aimed at inhibiting inflammation and immunosuppression or immunomodulation against the risks of serious adverse effects and other drawbacks, such as the inconvenience and discomfort of infusions or injections. In this roundtable discussion, 2 experts in MS management review current and investigational treatments with a focus on newer sphingosine 1-phosphate (S1P) receptor modulators, which show promise in overcoming the limitations associated with current therapies.
At the conclusion of this activity, participants should be better able to:
- Implement individualized treatment planning and monitoring based on assessment of multiple sclerosis (MS) disease activity and progression
- Analyze efficacy and safety data of the approved and emerging sphingosine 1-phosphate (S1P) modulator therapies in MS and evaluate their risk-benefit profiles in relation to current disease-modifying therapies
- Engage patients with MS in shared decision-making in planning for long-term management
- Integrate effective communication and education strategies into practice to overcome common obstacles and promote adherence to treatment
Scott D. Newsome, DO, MSCS, FAAN
Associate Professor of Neurology
Johns Hopkins School of Medicine
Mark B. Skeen, MD
Associate Professor of Neurology
Duke University Medical Center
Durham, North Carolina
In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Haymarket Medical Education (HME). The CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
AMA PRA Category 1 CreditsTM
The Consortium of Multiple Sclerosis Centers (CMSC) designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ANCC Contact Hours
This activity is awarded 1.25 contact hours.
CE for Pharmacists
This knowledge-based activity JA4008165-9999-20-035-H01 qualifies for 1.25 contact hours (0.125 CEU) of continuing pharmacy education credit.
Accredited Provider Disclosure
The Consortium of Multiple Sclerosis Centers (CMSC) and Haymarket Medical Education (HME) staff, additional planners, and reviewers in a position to control the content of this activity have no relevant financial relationships to disclose.
Conflict of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, the Consortium of Multiple Sclerosis Centers (CMSC) and Haymarket Medical Education (HME) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. CMSC and HME resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational activities.
Disclosure of Unlabeled Use
This IPCE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this IPCE activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Consortium of Multiple Sclerosis Centers, Haymarket Medical Education, or Bristol Myers Squibb. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
If you have any questions relating to the accreditation of this activity, please contact [email protected].